share_log

万泰生物(603392.SH):九价HPV疫苗男性临床试验申请获得药物临床试验批准通知书

Beijing Wantai Biological Pharmacy Enterprise (603392.SH): Application for clinical trial of nine-valent HPV vaccine in males has received the drug clinical trial approval letter.

Gelonghui Finance ·  Nov 18, 2024 17:29

Gelonghui reported on November 18 that Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced that its wholly owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., received a "Clinical Trial Notification" issued by the National Medical Products Administration, agreeing to conduct clinical trials for the nine-valent human papillomavirus vaccine (Escherichia coli) (referred to as the "nine-valent HPV vaccine") for indications in the male population.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment